Drug intelligence / Profile preview

99mTc-CCMSH

Development stage
Preclinical
Lead developer
Michigan State University
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

**99mTc-CCMSH** is a radiolabeled peptide composed of the radioisotope technetium-99m (99mTc) chelated to CCMSH, a cyclic analog of the alpha-melanocyte-stimulating hormone (α-MSH). This compound acts as a targeted radiopharmaceutical, binding to the melanocortin 1 receptor (MC1R), which is highly expressed in melanoma cells. By targeting MC1R, 99mTc-CCMSH enables imaging of melanoma tumors using single-photon emission computed tomography (SPECT). It is primarily used in preclinical research and investigational nuclear medicine studies to detect and evaluate melanoma lesions. The agent exploits the high affinity of CCMSH for MC1R to deliver the radioisotope specifically to melanoma tissue, thus allowing sensitive tumor localization and staging. Its mechanism of action is receptor-mediated, based on the specific uptake and internalization by tumor cells expressing MC1R.

Other names
technetium-99m-CCMSHtechnetium99m-CCMSHtechnetium 99m-CCMSHtechnetium Tc-99m CCMSH
02

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on 99mTc-CCMSH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-CCMSH.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call